| ADTX 0.0127 -2.31% | SOXS 4.72 -5.03% | SPCX 160.95 19.22% | DFNS 0.233 -9.20% | BITO 8.65 0.12% | RUBI 0.4676 -24.62% | TZA 4.16 -2.58% | CAST 1.55 140.68% | AAL 14.98 2.25% | INTC 124.57 6.51% | SPCE 3.91 -31.76% | SHFS 0.276 16.46% | SRXH 0.148 17.65% | NOK 14.795 5.00% | NVDA 205.19 0.16% | BYAH 1.47 40.00% | SPDN 8.81 -0.45% | TQQQ 77.52 1.99% | TSLL 13.59 3.58% | PAVS 0.208 -28.28% | CPOP 0.195 -81.43% | SMCI 30.46 -4.72% | CUPR 3.97 64.73% | VSME 1.69 52.25% | YYGH 0.119 -3.25% | SQQQ 40.04 -1.93% | RKLB 102.39 -10.79% | TSLA 406.43 1.82% | NVD 5.02 -0.40% | WOK 0.0753 -17.70% | SPY 741.75 0.54% | ASTS 82.41 -15.53% | KEEL 5.59 1.27% | ONDS 9.33 -5.09% | SPYM 87.06 0.25% | AMZN 238.55 -1.23% | XLF 53.34 1.37% | SATS 114.08 -10.97% | QQQ 721.34 0.59% | SOFI 16.58 -0.54% | PLUG 2.76 -2.47% | SOXL 234.68 4.77% | GRAB 3.3 -1.49% | DRIP 4.74 -2.47% | AMC 2.34 2.63% | IREN 59.77 5.40% | HKIT 0.5025 -10.11% | RKLZ 3.01 21.37% | RZLV 2.68 5.93% | MARA 14.08 3.45%

Establishment Labs Holdings Inc. (NASDAQ: ESTA) Surpasses Revenue Estimates

Establishment Labs Holdings Inc. (NASDAQ: ESTA) is a global medical technology company that focuses on enhancing women's health and wellness, particularly in breast aesthetics and reconstruction. On February 24, 2026, ESTA reported its earnings, revealing a revenue of approximately $64.6 million, which surpassed the estimated $63.8 million. This achievement highlights the company's ability to exceed market expectations.

Despite reporting a quarterly loss of $0.09 per share, ESTA's performance was significantly better than the Zacks Consensus Estimate of a loss of $0.22 per share. This marks a substantial improvement from the previous year's loss of $0.98 per share, indicating a positive trend in the company's financial performance. The improvement in earnings per share suggests that ESTA is making strides in managing its expenses and improving profitability.

The company's fourth-quarter revenue of $64.6 million represents a significant increase of 45.2% compared to the same period last year. For the entire year of 2025, ESTA achieved a revenue of $211.1 million. This growth reflects the company's successful strategies in expanding its operations and capturing a larger market share in the medical technology sector.

ESTA's financial metrics reveal some challenges, such as a negative price-to-earnings (P/E) ratio of -42.77 and an earnings yield of -2.34%, indicating negative earnings. However, the company's price-to-sales ratio of 10.15 and enterprise value to sales ratio of 9.80 suggest that investors are willing to pay a premium for its sales, reflecting confidence in its future growth potential.

The company's debt-to-equity ratio is relatively low at 0.12, indicating a conservative use of debt in its capital structure. Additionally, ESTA's current ratio of 3.04 demonstrates a strong liquidity position, ensuring the company can cover its short-term liabilities. These financial metrics suggest that while ESTA faces challenges in generating positive earnings, it maintains a solid financial foundation to support its growth initiatives.

Published on: February 24, 2026